updated 2/4/2011 11:16:33 AM ET 2011-02-04T16:16:33

NEW YORK, Feb. 4, 2011 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc. to discuss the company's industry, strategy, financials and positioning.

Click here to view video:

http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=44274&k=AA2E8FCF07AF781D85F1A2FA5D74AB47

Keith A. Katkin, President and Chief Executive Officer, AVANIR Pharmaceuticals, Inc.

Mr. Katkin joined AVANIR in July 2005 as Senior Vice President of Sales and Marketing. In March 2007, Mr. Katkin was appointed President and Chief Executive Officer and was elected as a member of the Board of Directors. Prior to joining AVANIR, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, playing a key role in the management of the company and its sale to Johnson and Johnson. Additionally, Mr. Katkin's employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories.

Mr. Katkin received a Bachelor of Science degree in Business and Accounting from Indiana University and an MBA degree in Finance from the Anderson School of Management at UCLA, graduating with honors. Mr. Katkin became a licensed Certified Public Accountant in 1995.

About AVANIR Pharmaceuticals, Inc. (AVNR):

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. The Company recently received approval from the U.S. Food and Drug Administration (FDA) for NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate), the first and only FDA-approved treatment for pseudobulbar affect (PBA), a neurologic condition causing involuntary, sudden and frequent episodes of laughing and crying. For the full Prescribing Information and Important Safety Information, please visit www.NUEDEXTA.com , and for more information about AVANIR, please visit www.avanir.com .

For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.48%
$30K home equity loan FICO 5.80%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com